AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32991656 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-placement (EP) group
Number of subjects: 20
Study 35647831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus metformin (AEM)
Number of subjects: 40
Study 35647831 — intervention group
Group type: COMPARATOR
Intervention: Metformin only (M)
Number of subjects: 40
Study 34213061 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab in combination with pomalidomide and dexamethasone (IsaPd)
Number of subjects: 0
Study 34213061 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide plus dexamethasone (Pd)
Number of subjects: 0
Study 34633853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin mesylate salt tablet, 1,500 mg single dose or 6,000 mg total (2 doses of 3,000 mg each, administered 6 or 12 hours apart)
Number of subjects: 59
Study 34633853 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin mesylate salt tablet, 6,000 mg total (2 doses)
Number of subjects: 59
Study 34633853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 32556764 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (Laparoscopic Totally Extraperitoneal)
Number of subjects: 145
Study 32556764 — intervention group
Group type: COMPARATOR
Intervention: TAPP (Transabdominal Pre-peritoneal)
Number of subjects: 145
Study 32556764 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 145
Study 32556764 — intervention group
Group type: COMPARATOR
Intervention: TAPP
Number of subjects: 145
Study 34578808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sil-Q1 (SQ; silk peptide) 7.5 g for 8 weeks
Number of subjects: 130
Study 34578808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 35268039 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein-based formula
Number of subjects: 20
Study 35268039 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (cow's milk protein-based)
Number of subjects: 20
Study 35268039 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free formula
Number of subjects: 20
Study 33764994 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus fatty acids (Intralipid plus heparin)
Number of subjects: 0
Study 33764994 — intervention group
Group type: COMPARATOR
Intervention: Saline/heparin
Number of subjects: 0
Study 35926989 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based day surgery management mode
Number of subjects: 1000
Study 35926989 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical services
Number of subjects: 1000
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: isotretinoin 0.5‐1 mg/kg/day for 24 weeks
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: isotretinoin 0.25‐0.4 mg/kg/day for 24 weeks
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: isotretinoin 0.5‐0.7 mg/kg/day for 1 week out of every 4 weeks for 24 weeks
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial GAGS score of 25-30
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial GAGS score of 19-24
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group <20 years among relapsed patients
Number of subjects: 107
Study 36346039 — intervention group
Group type: EXPERIMENTAL
Intervention: GAGS as a predictor of relapse
Number of subjects: 107
Study 33874903 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant inbred line (RIL) population derived from 'Hanoch' and 'Harari'
Number of subjects: 2
Study 33874903 — intervention group
Group type: EXPERIMENTAL
Intervention: QTL regions for MI identified on chromosomes A04 and B03
Number of subjects: 2
Study 33874903 — intervention group
Group type: EXPERIMENTAL
Intervention: QTL for harvest index (HI)
Number of subjects: 2
Study 33874903 — intervention group
Group type: EXPERIMENTAL
Intervention: Effects on MI from branching habit (BH), pod yield, and shelling percentage (SP)
Number of subjects: 2
Study 32744045 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training (30 min, 3 days a week for 10 weeks)
Number of subjects: 45
Study 32744045 — intervention group
Group type: COMPARATOR
Intervention: Routine training (Control group one)
Number of subjects: 45
Study 32744045 — intervention group
Group type: COMPARATOR
Intervention: Unstructured football training (Control group two)
Number of subjects: 45
Study 36153555 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital format of the German schizophrenia guideline using the evidence ecosystem MAGICapp
Number of subjects: 0
Study 32613329 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg of elemental iron in combined iron–folic acid pills) from 12 weeks of gestation until delivery
Number of subjects: 0
Study 32602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance policies
Number of subjects: 377
Study 32602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Norm deviation (deviating from corona regulations)
Number of subjects: 377
Study 32602596 — intervention group
Group type: EXPERIMENTAL
Intervention: Norm-violating outgroup members
Number of subjects: 377
Study 34433548 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct selective laser trabeculoplasty (DSLT): 120 shots, 3 ns, 400 µm spot size, energy 1.4‐1.8 mJ delivered at the limbus over 2 s.
Number of subjects: 164
Study 34433548 — intervention group
Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT): approximately 100 shots, 3 ns, 400 µm spot size administered 360 degrees at the limbus using any gonioscopy lens, energy 0.3‐2.6 mJ.
Number of subjects: 164
Study 34391284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 48
Study 34391284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + Mobilization (AE + M)
Number of subjects: 48
Study 34391284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 34904799 — intervention group
Group type: EXPERIMENTAL
Intervention: pola-R-CHP
Number of subjects: 879
Study 34904799 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 879
Study 34748164 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of long-term antidepressant medication
Number of subjects: 478
Study 34748164 — intervention group
Group type: COMPARATOR
Intervention: Long-term maintenance antidepressants
Number of subjects: 478
Study 34893973 — intervention group
Group type: EXPERIMENTAL
Intervention: four behavioural self‐management sessions
Number of subjects: 228
Study 34893973 — intervention group
Group type: COMPARATOR
Intervention: generic health information
Number of subjects: 228
Study 32668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey protein-based infant formula (PHF)
Number of subjects: 268
Study 32668666 — intervention group
Group type: COMPARATOR
Intervention: Intact cow’s milk protein formula (IPF)
Number of subjects: 268
Study 36018730 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercises for 3 months
Number of subjects: 61
Study 36018730 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise program (control group)
Number of subjects: 61
Study 33504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EPO and standard-of-care (SOC)
Number of subjects: 20
Study 33504262 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) alone
Number of subjects: 20
Study 33504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EPO and SOC
Number of subjects: 20
Study 33504262 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 20
Study 33504262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EPO
Number of subjects: 20
Study 35162787 — intervention group
Group type: EXPERIMENTAL
Intervention: P1:7
Number of subjects: 6
Study 35162787 — intervention group
Group type: EXPERIMENTAL
Intervention: RHIT1:6
Number of subjects: 6
Study 35162787 — intervention group
Group type: EXPERIMENTAL
Intervention: RHIT1:7
Number of subjects: 6
Study 35162787 — intervention group
Group type: EXPERIMENTAL
Intervention: P1:6
Number of subjects: 6
Study 35162787 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSRT
Number of subjects: 6
Study 35162787 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study 33744327 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0214 15 mg QD
Number of subjects: 36
Study 33744327 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0214 15 mg twice daily
Number of subjects: 36
Study 33744327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32533819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 20
Study 32533819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34936514 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing target width after every other training block
Number of subjects: 2
Study 34936514 — intervention group
Group type: COMPARATOR
Intervention: Constant target width
Number of subjects: 2
Study 32167974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 159
Study 32167974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 33388075 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered nutritional intervention
Number of subjects: 74
Study 33388075 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 32140784 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (0.75 μg)
Number of subjects: 0
Study 32140784 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1.0 μg)
Number of subjects: 0
Study 32140784 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Number of subjects: 0
Study 32140784 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 0
Study 35036429 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine beverage intake before exercise
Number of subjects: 36
Study 35036429 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine beverage intake immediately after exercise
Number of subjects: 36
Study 35036429 — intervention group
Group type: COMPARATOR
Intervention: Exercise without caffeine consumption
Number of subjects: 36
Study 33430819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 41
Study 33430819 — intervention group
Group type: COMPARATOR
Intervention: Blue light conventional phototherapy
Number of subjects: 41
Study 33430819 — intervention group
Group type: COMPARATOR
Intervention: White light conventional phototherapy
Number of subjects: 41
Study 36075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam at doses of 0.25–0.33 mg kg−1 for patients aged <40
Number of subjects: 3
Study 36075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam at doses of 0.19–0.25 mg kg−1 for patients aged 40–60
Number of subjects: 3
Study 36075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam at doses of 0.14–0.19 mg kg−1 for patients aged 60–80
Number of subjects: 3
Study 33481053 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable platelet-rich fibrin (i-PRF) injected into the mucosa on the buccal and palatal aspects of the intervention sides, repeated one month later
Number of subjects: 21
Study 33481053 — intervention group
Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 21
Study 32014709 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU)
Number of subjects: 236
Study 32014709 — intervention group
Group type: COMPARATOR
Intervention: Hospital follow-up (HFU)
Number of subjects: 236
Study 34965945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET)
Number of subjects: 672
Study 34965945 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (ET)
Number of subjects: 672
Study 34965945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus ET
Number of subjects: 672
Study 34965945 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ET
Number of subjects: 672
Study 34351946 — intervention group
Group type: COMPARATOR
Intervention: 50 Hz magnetic field exposure (real MF)
Number of subjects: 0
Study 34351946 — intervention group
Group type: COMPARATOR
Intervention: 50 Hz magnetic field exposure (real MF in neck region)
Number of subjects: 0
Study 34351946 — intervention group
Group type: COMPARATOR
Intervention: 50 Hz magnetic field exposure (real MF in upper arm region)
Number of subjects: 0
Study 32458557 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD) condition, sleep duration 141.2 ± 13.3 min
Number of subjects: 10
Study 32458557 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (CON) condition, sleep duration 469.0 ± 2.3 min
Number of subjects: 10
Study 32458557 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min run at 65% of V˙ O2max on day 2
Number of subjects: 10
Study 35795023 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glutamate diet for 1 month
Number of subjects: 40
Study 35795023 — intervention group
Group type: COMPARATOR
Intervention: Monosodium glutamate (MSG)
Number of subjects: 40
Study 35795023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32343614 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-Hole Peg Test performance for the more affected hand
Number of subjects: 582
Study 32343614 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment Parkinson's Disease Disability Scale
Number of subjects: 582
Study 36378778 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 214
Study 36378778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 36378778 — intervention group
Group type: COMPARATOR
Intervention: Both groups (extended-release niacin and placebo)
Number of subjects: 214
Study 34232926 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 65
Study 34232926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 65
Study 33749066 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation, Paced Respiration, and Relaxation (PEPRR)
Number of subjects: 135
Study 33749066 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 135
Study 32798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (gender, age, treatment type)
Number of subjects: 200
Study 32798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients aged greater than 50 years
Number of subjects: 200
Study 32798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, age, and treatment type
Number of subjects: 200
Study 32798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 200
Study 36316873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful coloring intervention (viewing a 3-minute instructional video and coloring mandalas for at least 5 working days or 100 minutes in total during a 10-day period)
Number of subjects: 77
Study 36316873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful coloring intervention
Number of subjects: 77
Study 36316873 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 77
Study 35393852 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐Sphincter Anorectoplasty (TSARP)
Number of subjects: 112
Study 35393852 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Sagittal Anorectoplasty (PSARP)
Number of subjects: 112
Study 35393852 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Anterior Sagittal Anorectoplasty (ASARP)
Number of subjects: 112
Study 35393852 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ASARP
Number of subjects: 112
Study 32354652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ectoin® Eye Spray (EES09)
Number of subjects: 36
Study 32354652 — intervention group
Group type: COMPARATOR
Intervention: Tears Again® Eye Spray (TA)
Number of subjects: 36
Study 34756796 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hand therapy plus workplace-based educational intervention (Working Hands-ED) for 12 weeks
Number of subjects: 49
Study 34756796 — intervention group
Group type: COMPARATOR
Intervention: Standard hand therapy for 12 weeks
Number of subjects: 49
Study 34996108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dex (1ug/kg) with propofol (1 mg/kg)
Number of subjects: 30
Study 34996108 — intervention group
Group type: COMPARATOR
Intervention: IV propofol (1 mg/kg)
Number of subjects: 30
Study 35367070 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01B‐adjuvanted HBV surface antigen vaccine
Number of subjects: 30
Study 35367070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 30
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential airborne culturable fungi (RAF) exposure
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm season RAF concentrations
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold season RAF concentrations
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: RAF in bedrooms
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature and humidity
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: CO
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2
Number of subjects: 600
Study 34102580 — intervention group
Group type: EXPERIMENTAL
Intervention: Architectural characteristics, family-related information, and lifestyle behaviors
Number of subjects: 600
Study 32163508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and GS‐561937 (FPI) combination therapy started at 3 days post infection
Number of subjects: 36
Study 32163508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and GS‐561937 (FPI) combination therapy started at 5 days post infection
Number of subjects: 36
Study 32163508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen alone started on day 3
Number of subjects: 36
Study 32163508 — intervention group
Group type: EXPERIMENTAL
Intervention: FPI with ibuprofen started on day 3
Number of subjects: 36
Study 32163508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34870586 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work individualized management program
Number of subjects: 149
Study 34870586 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 149
Study 35594800 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-inclusive Instagram images
Number of subjects: 1025
Study 35594800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-normative Instagram images
Number of subjects: 1025
Study 35594800 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1025
Study 33676590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 420
Study 33676590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 400 mg
Number of subjects: 420
Study 33676590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 32739709 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT
Number of subjects: 62
Study 32739709 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 62
Study 35410921 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (shaving, disc excision or segmental resection)
Number of subjects: 352
Study 35410921 — intervention group
Group type: COMPARATOR
Intervention: Assisted reproductive technologies (ART) management (at least two IVF or ICSI procedures if not pregnant after the first cycle)
Number of subjects: 352
Study 35410921 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 352
Study 35410921 — intervention group
Group type: COMPARATOR
Intervention: Assisted reproductive technologies (ART) management
Number of subjects: 352
Study 33779203 — intervention group
Group type: EXPERIMENTAL
Intervention: WSWS2-L (long version with 19 items)
Number of subjects: 0
Study 33779203 — intervention group
Group type: EXPERIMENTAL
Intervention: WSWS2-B (brief version with 6 items)
Number of subjects: 0
Study 33779203 — intervention group
Group type: COMPARATOR
Intervention: WSWS (original version)
Number of subjects: 0
Study 32435906 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM)
Number of subjects: 36
Study 32435906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone applications
Number of subjects: 36
Study 32435906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 35861762 — intervention group
Group type: EXPERIMENTAL
Intervention: FAITH! App (immediate intervention)
Number of subjects: 85
Study 35861762 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention comparator group (control)
Number of subjects: 85
Study 32055866 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical demonstration
Number of subjects: 150
Study 32055866 — intervention group
Group type: COMPARATOR
Intervention: Written instruction
Number of subjects: 150
Study 34936984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and psychological interventions plus 3 karate sessions per week for 12 weeks
Number of subjects: 70
Study 34936984 — intervention group
Group type: COMPARATOR
Intervention: Nutritional and psychological interventions once a week for 12 weeks
Number of subjects: 70
Study 32888339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up (telephone follow-up by nurses)
Number of subjects: 385
Study 32888339 — intervention group
Group type: COMPARATOR
Intervention: Gynaecologist-led clinic follow-up
Number of subjects: 385
Study 35670658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-hypoglycemic phase (2.5 mmol/L) followed by recovery to hyperglycemia (20 mmol/L)
Number of subjects: 24